StockpollyBeta
Get App
Popularity #3,953
NNVC · AMEX · Biotechnology

NanoViricides (NNVC)

Develops host-mimetic antiviral candidates for multiple viral diseases.

$1.57
vs last close+0.04 (+2.61%)

  1. Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides

    AccesswireClinical

  2. Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in 
DR Congo with 48% Crude Fatality Rate, Says NanoViricides

    Accesswire

  3. Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo

    AccesswireClinical

  4. While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles

    AccesswireClinical

  5. NanoViricides (NYSE:NNVC) Trading Down 2.2% – Time to Sell?

    Defense WorldMarket move

  6. The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon

    AccesswireClinical

  7. NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

    Accesswire

  8. NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial

    Accesswire

  9. NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering

    Accesswire

  10. As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo

    Accesswire

  11. Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily

    Accesswire

  12. As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo

    Accesswire

  13. US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher

    Accesswire

  14. NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo

    Accesswire

  15. As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo

    Accesswire

  16. As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies

    Accesswire

  17. In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides

    Accesswire

  18. NanoViricides closes $2M direct offering

    Proactive Investors

  19. NanoViricides closes $2M direct offering

    Proactive Investors - Finance

  20. Nasdaq semis lead losses as bond yields put pressure on Iran talks

    Proactive Investors - Finance

  21. Cyclical stocks' strong run may be due a pause despite leading markets this year, leading bank warns

    Proactive Investors - Finance

  22. NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak

    Proactive Investors

  23. NanoViricides to raise $2M in registered direct offering

    Proactive Investors

  24. NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering

    Accesswire